Outil d'établissement de liens pour les subventions d'équipe La biologie au service de la prévention du cancer

Les subventions d'équipe La biologie au service de la prévention du cancer visent à mobiliser des équipes de recherche interdisciplinaires qui aspirent à faire progresser, dans une optique biologique et mécaniste, l'étiologie du cancer et la compréhension des divers facteurs de risque associés (hôte, mode de vie, environnement, contexte social, etc.) dans l'espoir de mettre en évidence de nouvelles cibles et méthodes pour prévenir la maladie, la détecter tôt et réduire ses risques d'apparition.

L'outil d'établissement de liens a vocation à mettre en relation les candidats au concours et à faciliter la formation des équipes de recherche et l'élaboration des demandes.

Il s'adresse aux chercheurs, aux utilisateurs des connaissances (c.-à-d. les personnes ayant une expérience concrète, les praticiens et les responsables des politiques) et aux partenaires candidats qui souhaitent échanger des renseignements ou établir une collaboration dans le cadre de la possibilité de financement. Pour être inclus dans l'outil, veuillez remplir le formulaire créé à cet effet. Les informations que vous transmettrez figureront dans le tableau ci-dessous. Ce dernier sera mis en ligne et fera l'objet de mises à jour régulières.

L'utilisation de l'outil d'établissement de liens ne constitue pas une exigence du processus de présentation d'une demande et ne procure aucun avantage particulier dans l'évaluation et le financement des demandes. Il n'est donc pas obligatoire de communiquer avec les personnes qui ont rendu leur information publique à l'aide de l'outil.

En remplissant le formulaire, vous consentez par ailleurs à ce que son contenu soit publié en l'étatNote en bas de page * dans la langue dans laquelle il a été soumis (français ou anglais). Sachez que vous pouvez à tout moment soumettre une demande de modification ou de retrait de vos renseignements en écrivant à cihr.icr@uhn.ca. Les demandes seront traitées périodiquement.

N'hésitez pas à adresser toute question au sujet du formulaire ou de l'outil à cihr.icr@uhn.ca.


Avis

L'information est fournie dans la langue dans laquelle le répondant l'a présentée.

Coordonnées Catégorie d'intervenants Classe(s) de financement d'intérêt Domaine de recherche et d'expertise Renseignements complémentaires

Canadian Partnership Against Cancer
Jean Yong
Health Economics Lead
Jean.Yong@PartnershipAgainstCancer.ca
Toronto, Canada

Applicant partner   As the steward of the Canadian Strategy for Cancer Control (the Strategy), the Canadian Partnership Against Cancer (the Partnership) receives ongoing funding from Health Canada to work with provincial and territorial ministries of health and their cancer programs, health system leaders and clinicians, and people affected by cancer across Canada to implement the Strategy to improve cancer outcomes for all people in Canada.

The Canadian Partnership Against Cancer's OncoSim is available for projects aimed at achieving the goals of the Canadian Strategy for Cancer Control. The OncoSim microsimulation model projects health and economic outcomes for various cancers, enabling users to create and compare scenarios with results that inform cancer service planning. In-kind support includes:

  • 24/7 online access to OncoSim.
  • Guidance on designing, conducting, and interpreting analyses.
  • Networking and collaboration opportunities with other users.

Providence Therapeutics
Jordan Schwartz
Director of Partnerships and Innovation
bd@providencetherapeutics.com
Calgary, Canada

Applicant partner   Providence Therapeutics (PTx) is an mRNA Medicines Platform company operating in the RNA field for 10 years. PTx has developed platforms for mRNA and lipid nanoparticle (LNP) medicines that stimulate immune responses to cancers and infectious diseases. Additionally, PTx is able to manufacture vaccines and therapeutics from personalized to pandemic scale. PTx's preclinical pipeline includes programs in oncology, infectious diseases, and animal health, developed both internally and with academic and industry partners. Furthermore, PTx has collaborations with UHN and OICR for research translation on the PTx platform. Providence Therapeutics offers a comprehensive mRNA Medicines Platform to interested researchers. PTx is committed to leveraging the potential of mRNA technology for the development of innovative mRNA medicines. PTx invites researchers to utilize its proven mRNA platform and LNP technology to translate their discoveries into clinical applications.

Health Canada's Food and Nutrition Directorate
bcs-bipc@hc-sc.gc.ca (Subject Line: CIHR Applicant Partner Opportunity on Ultra-Processed Foods)
Ottawa, Canada

Applicant partner Ultra-processed foods

Health Canada is the Federal department responsible for helping Canadians maintain and improve their health. Within Health Canada, the Food and Nutrition Directorate has the mandate to:

  • Assess risks associated with the food supply and mitigating those risks through setting standards, policies, and regulations;
  • Promote and support the nutritional health and well-being of Canadians; and
  • Provide advice and information regarding healthy eating, and the safety and nutritional quality of food.

The Food and Nutrition Directorate includes the Bureau of Chemical Safety and Bureau of Nutritional Sciences.

Health Canada is interested in projects that aim to better elucidate potential pathways by which ingredients or other substances in ultra-processed foods may affect biological mechanisms related to cancer risk or development. In-kind support may include:

  • Providing advice in nutrition and food chemical safety biomarkers and standards.
  • Collaboration on related laboratory activities (e.g., detection methods, understanding of cellular process underlying health impacts).
  • Organization of webinars or roundtable expert discussions to discuss research project results.
  • Facilitation of networking/ collaboration with other knowledge users (e.g., in other government departments).
  • Co-supervision of trainees and visiting scientists.

Canadian Nuclear Laboratories
Kate Huner
Director of Science and Technology Strategic Partnerships
kate.huner@cnl.ca
Chalk River, Canada

Applicant partner   The Canadian Nuclear Laboratories (CNL) is Canada's premier nuclear science and technology organization, and a world leader in developing nuclear technology for peaceful and innovative applications. Using our unique expertise, we are restoring and protecting the environment, we are advancing clean energy technology, and our medical breakthroughs continue to improve the health of people around the world. CNL's unique Biological Research Facility and irradiation capabilities enable iconic long-term in vivo studies of impact of radiation on health. For 75 years, CNL has been at the forefront of innovation in nuclear medicine, radiopharmaceuticals, and low dose radiation research.

CNL is interested in projects that aim to prevent cancer due to chronic exposure to low dose ionizing radiation that may happen in the environment, such as radon emission, in the workplace, or during repeated medical procedures. In-kind support may include:

  • Advice and expertise on experiments that involve in vivo investigations of biological response to exposure to low dose ionizing radiation.
  • Cancer development due to chronic exposure to low dose radiation.
  • Access to the CNL Low Dose Radiation Tissue Bank.
Date de modification :